Most people who come to see me about snoring or sleep apnoea are thinking about their sleep. What they are not thinking about is their kidneys, their bone density, their telomeres, or their risk of colorectal cancer. And I understand that. The connection between a noisy night and a blood test result feels abstract. But the evidence over the past decade has become impossible to ignore: untreated obstructive sleep apnoea is not simply a sleep problem. It is a whole-body condition that erodes health across virtually every organ system, often for years before anyone identifies what is driving the damage.
Before I go through each body system, let me explain how to read the evidence I will present, because the statistics used in medical research are not always intuitive. When researchers say something has an odds ratio of 2, they mean you are roughly twice as likely to develop that condition compared with someone who does not have the risk factor. A hazard ratio of 1.5 means your risk is roughly one and a half times higher. Rather than asking you to interpret these numbers yourself, I have converted every figure into plain English: for each condition, I give you the real-world baseline risk for the relevant group, then show you where that risk moves with untreated sleep apnoea. I also explain the types of studies involved, because not all evidence is equally convincing.
The mechanism running through almost all of this is the same. Every apnoea event, every moment the airway collapses and breathing stops, drops oxygen levels in the blood. The brain detects the crisis, floods the body with stress hormones, raises the heart rate, and forces an arousal from sleep just long enough to restore breathing. Then it happens again. In severe sleep apnoea this cycle repeats more than thirty times an hour. Multiply that by eight hours of sleep, then by 365 nights a year, then by the average seven years between the onset of symptoms and diagnosis in the UK, and the cumulative physiological damage becomes easier to understand.
OSA affects approximately 936 million adults worldwide aged 30 to 69. It is found in 40 to 80 per cent of patients attending cardiology clinics, most of it undiagnosed. The cost of leaving it untreated dwarfs the cost of finding and treating it.
What follows is a guide to what the research shows across each major body system. Each section links to a deeper page where I go through the full evidence in detail. This page is intended as a starting point.
The Brain: Dementia, Stroke, and Cognitive Function
The most striking finding from recent large-scale research is the link between OSA and dementia. Dementia affects roughly 1 in 11 people over 65. For those with untreated sleep apnoea, a 2025 analysis pooling data from 39 separate long-term studies puts that figure closer to 1 in 8. To make that concrete: imagine a village of 1,000 older adults. Without sleep apnoea, you would expect around 91 to develop dementia. With untreated OSA, that number rises to around 120. For Alzheimer's specifically, where the lifetime risk after 65 is roughly 1 in 14, untreated OSA moves it to closer to 1 in 10.
The mechanism is well understood: the brain clears waste products, including the amyloid proteins that define Alzheimer's pathology, almost entirely during deep sleep. Every apnoea event interrupts this nightly cleanse. OSA patients already have measurably higher blood levels of these Alzheimer's-associated proteins compared with healthy controls. Reassuringly, positive airway pressure (PAP) therapy was found protective in 9 out of 11 studies examining this question, delaying the onset of cognitive decline in those who used it consistently.
Stroke risk follows a similar pattern. For someone in their 50s or early 60s without other major risk factors, the ten-year stroke risk is roughly 1 in 25. With severe untreated sleep apnoea, that moves to closer to 1 in 12. The risk is dose-dependent: the more severe the OSA, the higher the risk. This dose-response pattern is exactly what scientists look for when assessing whether a relationship is genuinely causal, rather than coincidental. For people who have already had a stroke, consistent CPAP use was associated in observational studies with a dramatic reduction in recurrence risk. Read the full dementia evidence and stroke evidence.
The Heart: Cardiovascular Disease, Hypertension, and Atrial Fibrillation
The relationship between OSA and the heart is one of the most thoroughly researched areas in sleep medicine. Pooling the results of 24 studies, researchers found that OSA raises the risk of cardiovascular disease overall by 71 per cent. To put that in real terms: cardiovascular disease affects roughly 1 in 7 adults over 50 over a ten-year period. With severe untreated OSA, that moves to closer to 1 in 4. For cardiac death specifically, severe OSA is associated with nearly triple the risk compared with those without it.
The blood pressure finding is particularly striking and practically important. Around 70 to 85 per cent of people with resistant hypertension — meaning blood pressure that fails to come down despite taking three different medications — have obstructive sleep apnoea. CPAP therapy reduces systolic blood pressure by an average of 5 millimetres of mercury in this group, which translates, at a population level, to meaningful reductions in stroke and heart attack risk.
For atrial fibrillation, OSA patients are 88 per cent more likely to develop it — roughly doubling the risk. Among patients who undergo catheter ablation to correct AF, those with OSA are 70 per cent more likely to have the AF return. However, patients who use CPAP consistently after ablation reduce that recurrence risk by 72 per cent. These are some of the most actionable numbers in the field. Read the full cardiovascular evidence.
Cancer Risk
This is perhaps the most counterintuitive finding in the sleep apnoea literature. The mechanism involves intermittent nocturnal hypoxia — the repeated oxygen drops during apnoea events — which activates a molecular pathway that solid tumours use to drive their own growth, recruit new blood vessels, and resist being killed. When sleep apnoea creates those same low-oxygen conditions across the whole body, every night, the cancer biology concern becomes easier to understand.
In patients with the most severe nocturnal oxygen drops, cancer incidence is 28 to 43 per cent higher than in those without significant drops. Cancer mortality — the risk of dying from cancer — is nearly tripled compared with people who do not have significant nocturnal hypoxia. These figures come from a pooled analysis of 20 studies covering more than 5.3 million people, which makes the finding as statistically reliable as epidemiological evidence gets.
The risk varies by cancer type. Thyroid cancer risk is more than doubled. Lifetime melanoma risk rises from roughly 1 in 40 to about 1 in 23. Colorectal cancer risk rises from roughly 1 in 22 to about 1 in 13. Breast cancer risk in women rises from 1 in 8 to roughly 1 in 6. These are real shifts in absolute risk, not just percentages that look dramatic but mean little in practice. Read the full cancer evidence.
Metabolism: Diabetes, Liver, and Weight
OSA patients are more than twice as likely to have type 2 diabetes. To express that as a real-world number: type 2 diabetes affects roughly 1 in 12 UK adults. With untreated OSA, that risk rises to approximately 1 in 5. In those under 50, the elevation is even steeper: more than three times the usual rate. Diabetes is found in 55 to 86 per cent of people already living with type 2 diabetes when they are tested systematically for sleep apnoea, making OSA the most common undiagnosed sleep condition in that group.
A pooled analysis of 11 randomised trials found that CPAP reduces HbA1c — the blood test that measures average blood glucose over three months — by an average of 0.24 per cent. To put that in context, most diabetes medications aim for an HbA1c reduction of 0.5 to 1 per cent, so 0.24 per cent is a meaningful contribution, and it comes without medication side effects.
For the liver: research using a method called Mendelian randomisation — which uses people's genetic makeup as a kind of natural experiment to test whether one thing genuinely causes another, rather than simply being associated with it — has confirmed that OSA independently causes non-alcoholic fatty liver disease. This type of study is considerably more convincing than simply observing that two conditions tend to coexist, because it rules out the possibility that both are just common in the same kinds of people. Read the full metabolic evidence.
Mental Health: Depression and Anxiety
More than 1 in 3 people with untreated sleep apnoea have measurable depressive symptoms. Around 1 in 4 meet clinical criteria for a diagnosis of depression — roughly double the rate in the general UK population. People with OSA are twice as likely to develop depression over time, and the risk rises in proportion to OSA severity: the more apnoea events per hour, the higher the depression risk. This pattern of increasing risk with increasing severity is one of the hallmarks of a genuine biological relationship rather than a coincidental one.
CPAP therapy reduces the odds of depression by 20 per cent across a pooled analysis of 20 randomised trials, with the greatest benefit in those who had significant depressive symptoms before treatment began. The implications of this for clinical practice are significant: many patients whose depression has responded only partially to antidepressants may have an underlying airway problem that has never been identified. Read the full mental health evidence.
Hormones and Sexual Function
For men, sleep apnoea has a direct and measurable effect on testosterone. Multiple analyses confirm significantly lower testosterone in men with OSA — independent of age and body weight, meaning the OSA is suppressing testosterone in its own right, not merely as a side effect of being older or heavier. Men with OSA are 82 per cent more likely to have erectile dysfunction — meaning the risk is nearly doubled. CPAP therapy significantly improves erectile function scores in men with OSA, with improvements seen across all trials that measured this.
For women, OSA is present in 37 to 40 per cent of those with polycystic ovary syndrome (PCOS), compared with just 6 per cent of women without PCOS. Women with PCOS are 9.5 times more likely to have OSA overall. During pregnancy, sleep apnoea is associated with a 2.8-fold higher risk of pre-eclampsia: where the condition normally affects about 1 in 14 pregnancies, that rises to roughly 1 in 5 with OSA. Mendelian randomisation studies have confirmed this is a causal link rather than coincidence. Men's health evidence and women's health evidence.
Biological Ageing and Skin
OSA accelerates biological ageing at a cellular level. The chronic oxidative stress from repeated oxygen crashes shortens telomeres — the protective caps on chromosomes that determine how many more times a cell can safely divide. Think of them like the plastic tips on a shoelace: when they wear down, the structure underneath becomes vulnerable. A systematic review confirmed that OSA patients have significantly shorter telomeres than people of the same age without OSA, and the shortening is worse the more severe the condition. OSA patients also show measurable epigenetic age acceleration: when biological age is measured using DNA patterns (which predict health and mortality better than the date on your birth certificate), OSA patients register as older than they actually are. Read the full evidence on OSA and ageing.
Kidneys, Bones, Eyes, and Hearing
The reach of sleep apnoea into organs most people would never associate with a breathing problem during sleep is remarkable. Kidney disease affects roughly 1 in 7 UK adults. OSA raises that risk by 77 per cent, bringing it to about 1 in 4. Having both OSA and kidney disease simultaneously more than doubles mortality compared with kidney disease alone.
Osteoporosis is roughly twice as common in OSA patients, independent of age and weight. Glaucoma risk is elevated by 50 to 96 per cent. A condition called nonarteritic anterior ischaemic optic neuropathy — a stroke of the optic nerve that causes sudden, often permanent, vision loss — is nearly four times more likely in people with OSA. Hearing impairment is 38 per cent more common in OSA patients, particularly at the high frequencies most important for understanding speech. Kidney evidence, eye evidence, and bones, joints and hearing evidence.
Children: Behaviour, Learning, and ADHD
Sleep apnoea is not a condition of middle-aged men. It is common in children, usually caused by enlarged tonsils and adenoids, and its effects during the developmental years are particularly consequential. A pooled analysis found that children with sleep-disordered breathing perform significantly worse academically — the gap is equivalent to roughly one grade level in language arts, maths, and science compared with children without the condition.
Untreated OSA in children is one of the most commonly missed diagnoses behind an apparent ADHD label. The hyperactivity, inattention, and impulsivity driven by chronic sleep fragmentation are neurologically indistinguishable from ADHD on a standard questionnaire. Treating the airway problem — often through adenotonsillectomy — frequently produces dramatic improvements in behaviour without any medication. Read the children's evidence.
Driving and Workplace Safety
People with untreated OSA are more than twice as likely to be involved in a road traffic accident. This is not primarily about falling asleep at the wheel, though that happens: it is about the specific impairment of sustained attention and reaction time that results from fragmented sleep architecture. EU law restricts driving licences for those with untreated moderate-to-severe OSA, and UK DVLA guidance requires drivers to disclose a diagnosis that causes excessive sleepiness. Workers with OSA have nearly double the odds of a workplace accident compared with colleagues without the condition. Read the driving and safety evidence.
A Note on Treatment
The evidence across almost every system shows some treatment signal. CPAP, when worn consistently — typically defined as more than four hours per night — lowers blood pressure, reduces depressive symptoms, slows cognitive decline, reduces recurrent atrial fibrillation, improves blood glucose control in diabetics, and improves sexual function. The challenge is that CPAP adherence is poor in clinical practice: around 83 per cent of patients stop using it long-term. This is why surgical and other treatment options matter, and why the choice of treatment should be personalised to the individual.
The most important message I want to leave you with is not that sleep apnoea is frightening. It is that it is treatable, it is enormously underdiagnosed, and the damage it causes is not inevitable. If you recognise yourself or someone you care about in what you have read here, getting a proper sleep study and a clinical assessment is a reasonable and relatively simple next step.
References
[1] Pintilie A-L et al. Sleep Apnea: The Slept-Upon Cardiovascular Risk Factor. Biomedicines. 2025. Narrative review reporting OSA affects approximately 936 million adults aged 30-69 worldwide and is found in 40-80% of cardiology clinic patients.
[2] Ungvári Z et al. Sleep disorders increase the risk of dementia, Alzheimer's disease, and cognitive decline: a meta-analysis. GeroScience. 2025. 39 cohort studies; Hazard Ratio for all-cause dementia 1.33, for Alzheimer's disease 1.45.
[3] Xie C-J et al. Association of obstructive sleep apnoea with the risk of vascular outcomes and all-cause mortality: a meta-analysis. BMJ Open. 2017. 16 cohort studies, 24,308 individuals; severe OSA associated with RR 2.15 for stroke, RR 2.96 for cardiac death.
[4] Salari N et al. The effect of obstructive sleep apnea on the increased risk of cardiovascular disease: a systematic review and meta-analysis. Neurological Sciences. 2021. 24 studies; OR 1.71 for cardiovascular disease overall.
[5] Tan BKJ et al. Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality. Journal of Clinical Sleep Medicine. 2022. 20 observational studies, 5.3 million participants; severe nocturnal hypoxia associated with 28-43% higher cancer risk and nearly tripled cancer mortality.
[6] Wang C et al. Obstructive sleep apnea, prediabetes and progression of type 2 diabetes: a systematic review and meta-analysis. Journal of Diabetes Investigation. 2022. 25 studies, 154,948 patients; OSA associated with more than doubled diabetes risk.
[7] Lu Q et al. Sleep disturbances during pregnancy and adverse maternal and fetal outcomes: a systematic review and meta-analysis. Sleep Medicine Reviews. 2021. 120 studies, 58 million pregnant women; OSA associated with OR 2.80 for pre-eclampsia.
[8] Galland BC et al. Sleep disordered breathing and academic performance: a meta-analysis. Pediatrics. 2015. Effect sizes -0.31 (language arts), -0.33 (mathematics), -0.29 (science) in school-aged children with sleep-disordered breathing.
[9] Luzzi V et al. Correlations of obstructive sleep apnea syndrome and daytime sleepiness with the risk of car accidents. Journal of Clinical Medicine. 2022. 49 studies; OR 2.36 for road traffic accidents in OSA patients.
Contact Professor Vik Veer
If you would like to discuss a sleep assessment or arrange a consultation, please use the details below.
Private secretary: 0207 458 4584